Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat and metformin for treatment of nonalcoholic fatty liver disease
IRCT2016031827097N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of orlistat and metformin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Ardabil University of Medical Sciences. Started Mar 2016; status: completed.
02
Drugs
orlistatmetformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT2016031827097N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016031827097N1.